Spinraza
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
January 19, 2026Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …
Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy
July 2, 2019Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy
Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …
NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza
May 15, 2019Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …
Top Ten most popular articles on Pharmafile.com this week
September 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10
With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …
Protesters in Manchester call on NICE to approve Biogen’s $750,000 drug Spinraza
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Spinraza, approval, protest, sma
Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …
NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay
August 14, 2018Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy
UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …
Biogen boosts pipeline with $1bn Ionis deal
April 23, 2018Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical
Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …
Biogen’s Spinraza to go before NICE
January 22, 2018Sales and Marketing Biogen, Spinraza, biotech, drugs, pharma, pharmaceutical
Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …
EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza
April 25, 2017Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy
Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …
